See more : Cyteir Therapeutics, Inc. (CYT) Income Statement Analysis – Financial Results
Complete financial analysis of Lixte Biotechnology Holdings, Inc. (LIXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lixte Biotechnology Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Macnica Galaxy Inc. (6227.TWO) Income Statement Analysis – Financial Results
- Perma-Pipe International Holdings, Inc. (PPIH) Income Statement Analysis – Financial Results
- Barsele Minerals Corp. (BME.V) Income Statement Analysis – Financial Results
- Conduit Holdings Limited (CRE.L) Income Statement Analysis – Financial Results
- Diversified Oil & Gas Holdings, Ltd. (DVFI) Income Statement Analysis – Financial Results
Lixte Biotechnology Holdings, Inc. (LIXT)
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 898.10K | 1.35M | 1.74M | 1.22M | 820.91K | 40.70K | 467.26K | 1.30M | 2.09M | 1.12M | 879.89K | 1.01M | 1.33M | 445.54K | 496.52K | 608.73K | 423.83K | 150.10K | 0.00 |
| General & Administrative | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 32.87K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 33.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.00K | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| Operating Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Cost & Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Interest Income | 1.25K | 11.20K | 626.00 | 5.23K | 49.72K | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 155.00 | 3.26K | 10.55K | 11.90K | 0.00 |
| Interest Expense | 0.00 | 8.88K | 7.41K | 3.67K | 0.00 | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 1.23K | 1.23K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 205.77K | 363.11K | 3.00 | 8.00 | 199.84K | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| EBITDA | 3.21K | -1.05K | -7.95K | 1.56K | -2.49M | 4.92K | 1.38K | 183.00 | -2.44M | -2.40M | -1.37M | -3.58M | -1.87M | -881.68K | -1.55M | -1.27M | -1.65M | -561.62K | -32.87K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,220.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.09M | -6.31M | -6.72M | -3.27M | -2.49M | -2.14M | -1.81M | -2.13M | -2.65M | -2.40M | -1.37M | -2.11M | -1.87M | -881.68K | -1.55M | -1.27M | -1.66M | -499.98K | -32.87K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,323.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.21K | -1.05K | -7.95K | 1.56K | 49.72K | 4.92K | 1.38K | 183.00 | -205.70K | -363.05K | 3.00 | -1.47M | -199.71K | 1.43K | -1.08K | 2.03K | 10.55K | -38.10K | 0.00 |
| Income Before Tax | -5.09M | -6.31M | -6.73M | -3.26M | -2.44M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.82K | 6.79K | -1.56K | -49.72K | -9.85K | -1.81K | -2.13K | -78.00 | -66.00 | 0.00 | -8.00 | -125.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.10K | 32.87K |
| Net Income | -5.09M | -6.30M | -6.74M | -3.26M | -2.39M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | -32.87K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.91M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.00K | 797.00K | 779.00K | 740.00K | 693.00K | 649.00K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
| Weighted Avg Shares Out (Dil) | 1.92M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.29K | 797.93K | 779.89K | 740.09K | 693.05K | 649.76K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings , Inc. (Nasdaq: LIXT) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of the world's leading comprehensive cancer centers, and Oncode Institute, Utrecht,...
Lixte Biotechnology's LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
A series of recent pre - clinical reports demonstrat e s LB-100's effectiveness in various non - neoplastic diseases that may benefit from PP2A inhibition
Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now
Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) has announced that its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer (SCLC). Dr. Ravi Salgia is the...
LIXTE BIOTECHNOLOGY'S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
A Pre-Clinical Study Reports that LB -100 Potentiates Standard Therapy f or Small Cell Lung Cancer Providing a Strong Rational e f or a Clinical Trial o f LB -100 i n Small Cell Lung Cancer Recently Initiated a t...
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating that inhibition of protein phosphatase 2A (PP2A) with LB-100...
Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine's Cancer Biology program, was selected...
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
Presentation to highlight Company's current clinical stud y of lead compound LB-100 for Small Cell Lung Cancer
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
EAST SETAUKET, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the enrollment of the first patient in a Phase...
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq : LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair.
Source: https://incomestatements.info
Category: Stock Reports